Danish Life Science Webinar on Dec. 15th, 2021 (Wed) From 17:00 (JPN)/09:00 (DK)

What makes Personalized Medicine Effective?
~Utilizing Biobank and Access to Real-World Data~

Host: Royal Danish Embassy

Support: Japan Pharmaceutical Manufacturers Association
               Japan Bioindustry Association (plan)
               Life Science Innovation Network Japan: LINK-J (Plan)

Zoom Operator: KY Trading

Contact: Rumi IIDA, Royal Danish Embassy, Invest in Denmark/ Email: rumiid**um.dk
(Please change ** to @ when sending message)

Registration link: Sign up here (deadline: Dec. 14th 2021 (Tue))

(Link to participate in webinar will be sent to the registered persons a few days before webinar.)

*) All Presentations are conducted in English (and/or Japanese) with the Japanese subtitle and/or simultaneous interpretation.
*) A part of the program might be changed.

************************* PROGRAM *********************************

17:00   Welcome by Mr. Magnus Heunicke, Health Minister (Video Message)

17:05   General introduction of Denmark and the Danish Healthcare System
              Rumi Iida, Investment Manager, Invest in Denmark, Tokyo

17:15~ 18:15   Presentation (Video Presentation)

   1. *"Personalized Medicine - for the Benefit of the Patients"*
      Mr. Rasmus Beedholm-Ebsen, Ph.D., Special Advisor (Life Science), Invest in Denmark
          Ministry of Foreign Affairs of Denmark

   2. *"The Danish National Biobank"*
      Mr. Lasse Boding
      Head of Coordinating Center, Danish National Biobank

3. ***"Bio- and GenomeBank Denmark – how was it established and how to collaborate"***
Ms. Estrid Høgdall, Ph.D.
Clinical Professor and Director of the Nationwide Bio- and GenomeBank Denmark

4. ***"About the Danish National Genome Center"***
Ms. Bettina Lundgren, CEO, Danish National Genome Center

5. ***"The Danish Health Data Authority and the National Health Data Landscape"***
Ms. Lisbeth Nielsen, Director General, Danish Health Data Authority

18:15   Q&A (Ms. Estrid Høgdall and Mr. Rasmus Beedholm-Ebsen will participate)

18:25   Closing remarks
Ms. Anne-Marie Christina Thoft, Special Advisor (Life Science), Invest in Denmark
Ministry of Foreign Affairs of Denmark

18:30   END

BIO for Dr. Rasmus Beedholm-Ebsen

Rasmus Beedholm-Ebsen is Senior Advisor within Life Science, at Invest in Denmark, under the Ministry of Foreign Affairs of Denmark. Rasmus received his PhD in Medicine at Aarhus University, Denmark, and worked at the Department of Medical Biochemistry at Aarhus University before joining Invest in Denmark. Most recently Rasmus received a degree in Master in Business Administration (MBA). Rasmus also holds a Bachelor of Commerce degree. Besides his PhD, Rasmus also have a Master degree in Molecular Biology, and is Scientific Expert Reviewer for the European Commission.

Lasse Boding
Head of Coordinating Centre
Danish National Biobank
Statens Serum Institut

Lasse Boding is heading the Coordinating Centre at the Danish National Biobank (DNB). He holds an MSc in biochemistry and a PhD in biomedicine from the University of Copenhagen.

Lasse is coordinating the research activities and responsible for securing smooth access to biological samples and corresponding data from the DNB.

DNB was created to strengthen the Danish research infrastructure and thereby the conditions for Danish public health research and international research collaborations. The biobank is one of the world's largest biobanks and internationally an absolutely unique resource to the great benefit of research in the etiology, prevention and treatment of diseases.

The biobank currently stores 8.5 million biological samples and via the Danish Biobank Register provides an overview of 24.5 million samples from 5.7 million donors stored in Danish biobanks. With direct link to register information, researchers can find samples from patients with a specific disease, and even identify samples taken many years before disease manifestation.

The Danish National Biobank is a joint initiative between Statens Serum Institut, hospitals, universities and other public research institutions collecting or using biological material.
For further information, please visit www.danishnationalbiobank.com

Bio for Dr. Estrid V.S. Høgdall

I am Clinical professor in molecular pathology at University of Copenhagen and Head of Molecular Unit, Department of Pathology. I am director of the Nationwide Bio –and Genome Bank Denmark which include Danish CancerBiobank (DCB), Danish RheumatologyBiobank (DRB), Danish Diabetes Biobank (DDB), Danish GeneticBiobank (DGB) and Danish BlooddonorBiobank (DBB). I am responsible for the management, guideline description and programming of the database module. More nationwide biobanks are planned with me as Director of the Secretry placed at Department of Pathology, Herlev Hospital. The biobanks are founded by Danish Regions

Career track records are documented in the areas: Molecular pathology, biobanking and various tumor profiling expression analyses. Special focus and experience in biomarkers of colorectal and ovarian tumors. I am being part of the established Ovarian Tumor Tissue Analysis (OTTA) Consortium, which consists of 30 studies including more than 8,000 ovarian cancer tissue samples. In the COGCs project – 7.th framework program – I was coordinating the ovarian cancer activity in the Workpackage 6. In hematology an international collaboration with Duke University, North Carolina, is started based on results established in a research study initiated from Department of Pathology, Herlev Hospital. I am attending Global Excellence through Department of Gynaecology and Oncology at Rigshospitalet with MD Anderson, Professor R. Bast. In this collaboration Molecular Unit will be partner and perform tissue micro arrays and different molecular analyses on sample material from both sites. As a part of Mermaid III the Molecular Unit performs methylations studies, miR studies and sequencing studies on tissue and blood samples from women diagnosed with ovarian tumors.

Global Excellence in Health Program:
https://www.rigshospitalet.dk/english/about-us/Pages/global-excellence.aspx?cookieAccept=1
Mermaid III Project:
https://www.mermaidprojektet.dk/wp-content/uploads/2017/04/Mermaid-III-the-challenge-of-ovarian-cancer.pdf

DANISH NATIONAL GENOME CENTER

BETTINA LUNDGREN
CEO, M.D., D.M.Sc.

Bettina Lundgren is CEO of Danish National Genome Center. Danish National Genome Center was established 1st of May 2019 and in operation 1st of July. The centre supports further development of personalised medicine in Denmark with new treatments through the use of knowledge and new technologies.

Bettina Lundgren has been CEO of Danish National Genome Center from 1st of September 2019 and leads the further establishment of the centre with a strong focus on patient outcome and the promotion of international and national cooperation within research and across the Danish Health Care system. Lundgren has contributed as chair, vice chair and member of numerous committees, including several clinical health councils (the Capital Region of Denmark) and chairman of the Genome Center for East Denmark. Her experience also includes chairing implementation of several large regional and national healthcare IT-system and quality initiatives.

She has a strong leadership profile, in-depth knowledge of the Danish healthcare system and extensive clinical experience from a range of clinical departments. Lundgren is a specialist in clinical microbiology and doctor of medical science (DMSc) from the University of Copenhagen. Prior to her appointment at Danish National Genome Center Lundgren has since 2010 been the centre director of more than 1,600 employees at Diagnostic Center Copenhagen University Hospital (Rigshospitalet). She has also been head of department at Hvidovre Hospital and at one of Denmark's largest research institutions in health, Statens Serum Institut (SSI). Lundgren's career spans over 19 years of management experience in the Danish health care system and broad research experience from a number of positions in and outside Denmark, including US National Institutes of Health (NIH), and she has contributed to more than 70 scientific publications. Degrees and professional experience 2019 – present: CEO, National Genome Center 2010 – 2019: Centre director, Diagnostic Centre Copenhagen University Hospital 2000 – 2010: Senior consultant, Hvidovre Hospital, Department of Clinical Microbiology 1999 – 2000: Head of department and consultant - Statens Serum Institut (SSI), Department of Mycobacteriology

Lisbeth Nielsen

Director General, Danish Health Data Authority

Lisbeth Nielsen's background is grounded in both the public and the private sector. In her current role as Director General at the Danish Health Data Authority, she works to create coherent and systematic health data solutions to benefit patients and practitioners as well as supporting general research and administrative tasks in the Danish health care sector. Before that, Lisbeth Nielsen worked as a Chief Quality Officer at North Zealand Hospital, as Assistant Director at Danish regions and as head of Health Care Sales at IBM. She holds a Master of Public Administration from the University of Roskilde

About The Danish Health Data Authority

The Danish Health Data Authority works to ensure better health for the Danish citizens through the use of data and by creating digital coherence in the healthcare sector.

The use of health data is a key element in the Danish healthcare system, and Denmark has some of the most comprehensive health registers in the world. We use health data to strengthen and develop the healthcare system and at the same time give the best treatment to each individual patient.

The Danish Health Data Authority is instrumental in providing coherent health data and digital solutions that benefit patients and practitioners as well as research and administrative purposes in the healthcare sector.

The Danish Health Data Authority is a part of The Ministry of Health and was established in November 2015. It is made up by an Executive Management, an Executive Secretariat and eight departments with approximately 300 employees.